We deliver complete lipid nanoparticle (LNP) solutions for effective siRNA delivery. We tailor the composition and preparation process of LNP based on an extensive understanding of customer requirements to address the needs of various target cells and application situations. Our evaluation process for LNP spans from in vitro cell tests through to in vivo animal tests to thoroughly assess delivery efficiency together with stability and safety before we optimize performance. Our commitment to strict quality control standards guarantees high-quality and consistent products in every batch while supporting drug development and precision medicine.
LNPs facilitate siRNA entry into target cells by interacting with cell membranes through mechanisms such as membrane fusion or endocytosis. This leads to enhanced gene silencing effects. Compared to conventional delivery methods, LNPs can achieve delivery efficiencies several to dozens of times higher, substantially improving siRNA bioavailability.
The lipid components in LNPs closely resemble the natural building blocks of human cell membranes, offering superior biocompatibility. They typically evoke minimal immune or cytotoxic responses in vivo, making LNPs ideal for delivering siRNA to a wide range of cells and tissues-including sensitive stem cells and immune cells-thus laying a strong foundation for clinical applications.
Surface modifications, such as PEGylation, increase LNP stability by prolonging circulation time and protecting siRNA from rapid degradation or clearance in the bloodstream. This enhances the probability of reaching target cells and improves overall delivery success.
We customize LNP formulations based on your siRNA sequence, target cell type, and delivery objectives (e.g., tissue targeting, intracellular localization). This involves optimizing the composition and ratios of cationic lipids, helper lipids, cholesterol, and PEGylated lipids to maximize delivery efficiency and stability.
Additionally, we fine-tune LNP particle size and surface charge through precise formulation techniques (e.g., microfluidics, lipid film extrusion) to meet diverse application needs.
We conduct in vitro transfection studies across various cell lines, evaluating siRNA uptake (using methods like fluorescent labeling) and gene silencing efficacy. Delivery formulations are then refined based on these results.
In vivo studies in animal models (mice, rats) further assess LNP biodistribution, targeting accuracy, bioavailability, and gene silencing duration through different administration routes (intravenous, local injection), providing critical insights to enhance in vivo delivery performance.
Our LNP surface modification strategies-such as PEGylation or polysaccharide coatings-improve stability both in vitro and in vivo by protecting siRNA from enzymatic degradation and immune clearance, thereby extending its half-life.
We also offer storage stability evaluations and optimization, identifying ideal conditions (temperature, pH, lyoprotectants) to maintain LNP structural and functional integrity during long-term storage.
In vitro cytotoxicity assays are performed to assess the impact of LNPs on cell viability, proliferation, and apoptosis across multiple cell types, ensuring biocompatibility.
In vivo safety assessments monitor physiological parameters (body weight, activity), blood biochemical markers (liver and kidney function, inflammatory cytokines), and histopathological changes post-administration to confirm the safety profile of our LNPs.
We talk with clients to understand their siRNA delivery goals, including target cells, efficiency needs, and experiment types. We assess feasibility and plan the delivery strategy and lipid nanoparticle composition.
Based on the discussion, we design a detailed plan for the LNP composition and preparation, selecting lipid types, ratios, siRNA-to-lipid ratios, preparation methods, and key parameters like particle size.
We prepare the lipid nanoparticles following the design, controlling conditions like temperature and mixing for quality and uniformity. Initial characterization (size, charge, shape) is done.
Using appropriate cell models, we test siRNA delivery efficiency, monitor cellular uptake, and gene silencing to verify the LNP function.
We conduct animal studies to examine distribution, targeting, bioavailability, and gene silencing effects, while monitoring safety and physiological indicators.
We collect and analyze data from all experiments to evaluate LNP performance and guide further improvements.
We provide detailed reports and discuss results with clients to decide if any optimization (composition, size, etc.) is needed to improve delivery.
Once approved, we produce LNPs at scale under GMP conditions, maintaining quality control to deliver consistent, high-quality products.
CustomizableWe tailor the lipid nanoparticle composition and preparation based on siRNA, target cells, and client needs. For example, we can add tumor-targeting ligands for better tumor cell delivery.
Expert TeamOur experienced scientists support every step-from consultation and design to experiments and data analysis-ensuring smooth project progress.
Strict Quality ControlWe have rigorous quality standards and testing at every stage, guaranteeing stable, uniform, and high-quality products that meet regulations and client requirements.
Yes, we can provide lipid nanoparticles with different component ratios. The optimal ratio is determined based on factors such as the siRNA sequence, target cell type, and delivery efficiency requirements. Typically, a series of in vitro and in vivo experiments-such as cellular uptake assays and gene silencing efficiency tests-are conducted to evaluate the performance of different formulations, enabling us to identify the best ratio that meets the specific needs of the customer.
Yes, quality testing reports for lipid nanoparticles can be provided. The reports include basic information about the lipid nanoparticles (such as product name, composition, batch number), test items (e.g., particle size, zeta potential, encapsulation efficiency, content, purity), testing methods, results, and conclusions regarding compliance with quality standards.
